Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse.

ABSTRACT: Chemotherapy resistance is a major obstacle to curing cancer patients. Combination drug regimens have shown promise as a method to overcome resistance; however, to date only some cancers have been cured with this method. Collateral sensitivity-the phenomenon whereby resistance to one drug is co-occurrent with sensitivity to a second drug-has been gaining traction as a promising new concept to guide rational design of combination regimens. Here we evolved over 100 subclones of the Eµ-Myc; p19^ARF-/- cell line to be resistant to one of four classical chemotherapy agents: doxorubicin, vincristine, paclitaxel, and cisplatin. We then surveyed collateral responses to acquisition of resistance to these agents. Although numerous collateral sensitivities have been documented for antibioti

SUBMITTER: Dalin S 

PROVIDER: S-EPMC8971507 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature